Literature DB >> 1827414

A radioiodinated linear vasopressin antagonist: a ligand with high affinity and specificity for V1a receptors.

A Schmidt1, S Audigier, C Barberis, S Jard, M Manning, A S Kolodziejczyk, W H Sawyer.   

Abstract

A linear vasopressin antagonist, Phaa-D-Tyr(Me)-Phe-Gln-Asn-Arg-Pro-Arg-Tyr-NH2 (Linear AVP Antag) (Phaa = Phenylacetyl), was monoiodinated at the phenyl moiety of the tyrosylamide residue at position 9. This antagonist appeared to be a highly potent anti-vasopressor peptide with a pA2 value in vivo of 8.94. It was demonstrated to bind to rat liver membrane preparations with a very high affinity (Kd = 0.06 nM). The affinity for the rat uterus oxytocin receptor was lower (Ki = 2.1 nM), and affinities for the rat kidney- and adenohypophysis-vasopressin receptors were much lower (Ki = 47 nM and 92 nM, respectively), resulting in a highly specific vasopressin V1a receptor ligand. Autoradiographical studies using rat brain slices showed that this ligand is a good tool for studies on vasopressin receptor localization and characterization.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1827414     DOI: 10.1016/0014-5793(91)80448-c

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  10 in total

Review 1.  Molecular neurobiology and pharmacology of the vasopressin/oxytocin receptor family.

Authors:  J Peter; H Burbach; R A Adan; S J Lolait; F W van Leeuwen; E Mezey; M Palkovits; C Barberis
Journal:  Cell Mol Neurobiol       Date:  1995-10       Impact factor: 5.046

2.  Modulation of parvalbumin interneuron number by developmentally transient neocortical vasopressin receptor 1a (V1aR).

Authors:  E A D Hammock; P Levitt
Journal:  Neuroscience       Date:  2012-07-20       Impact factor: 3.590

3.  High salt intake enhances swim stress-induced PVN vasopressin cell activation and active stress coping.

Authors:  N C Mitchell; T L Gilman; L C Daws; G M Toney
Journal:  Psychoneuroendocrinology       Date:  2018-04-06       Impact factor: 4.905

4.  Characterization of SR 121463A, a highly potent and selective, orally active vasopressin V2 receptor antagonist.

Authors:  C Serradeil-Le Gal; C Lacour; G Valette; G Garcia; L Foulon; G Galindo; L Bankir; B Pouzet; G Guillon; C Barberis; D Chicot; S Jard; P Vilain; C Garcia; E Marty; D Raufaste; G Brossard; D Nisato; J P Maffrand; G Le Fur
Journal:  J Clin Invest       Date:  1996-12-15       Impact factor: 14.808

5.  Novel strategies for the design of receptor-selective vasopressin analogues: Aib-substitution and retro-inverso transformation.

Authors:  J Howl; Z Prochazka; M Wheatley; J Slaninová
Journal:  Br J Pharmacol       Date:  1999-10       Impact factor: 8.739

6.  Biochemical and pharmacological properties of SR 49059, a new, potent, nonpeptide antagonist of rat and human vasopressin V1a receptors.

Authors:  C Serradeil-Le Gal; J Wagnon; C Garcia; C Lacour; P Guiraudou; B Christophe; G Villanova; D Nisato; J P Maffrand; G Le Fur
Journal:  J Clin Invest       Date:  1993-07       Impact factor: 14.808

Review 7.  Arginine vasopressin (AVP): a review of its historical perspectives, current research and multifunctional role in the hypothalamo-hypophysial system.

Authors:  Fabio Rotondo; Henriett Butz; Luis V Syro; George M Yousef; Antonio Di Ieva; Lina M Restrepo; Andres Quintanar-Stephano; Istvan Berczi; Kalman Kovacs
Journal:  Pituitary       Date:  2016-08       Impact factor: 4.107

Review 8.  Vasopressin and oxytocin receptor systems in the brain: Sex differences and sex-specific regulation of social behavior.

Authors:  Kelly M Dumais; Alexa H Veenema
Journal:  Front Neuroendocrinol       Date:  2015-05-04       Impact factor: 8.606

Review 9.  Oxytocin and vasopressin agonists and antagonists as research tools and potential therapeutics.

Authors:  M Manning; A Misicka; A Olma; K Bankowski; S Stoev; B Chini; T Durroux; B Mouillac; M Corbani; G Guillon
Journal:  J Neuroendocrinol       Date:  2012-04       Impact factor: 3.627

10.  AVPR1A distribution in the whole C57BL/6J mouse neonate.

Authors:  Katherine R Day; Alexis Coleman; Maria A Greenwood; Elizabeth A D Hammock
Journal:  Sci Rep       Date:  2020-09-03       Impact factor: 4.379

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.